Metsera, Inc. (NASDAQ:MTSR - Get Free Report) traded up 8.6% on Tuesday . The stock traded as high as $29.78 and last traded at $29.66. 114,937 shares were traded during trading, a decline of 87% from the average session volume of 883,583 shares. The stock had previously closed at $27.30.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on the company. Evercore ISI assumed coverage on Metsera in a report on Tuesday, February 25th. They set an "outperform" rating for the company. Guggenheim assumed coverage on Metsera in a report on Tuesday, February 25th. They set a "buy" rating and a $56.00 price objective for the company. Bank of America assumed coverage on Metsera in a report on Tuesday, February 25th. They set a "buy" rating and a $38.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on Metsera in a report on Tuesday, February 25th. They set an "overweight" rating for the company.
Check Out Our Latest Analysis on MTSR
Metsera Price Performance
The company has a fifty day simple moving average of $22.98.
Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. New York State Common Retirement Fund bought a new stake in Metsera during the 1st quarter valued at approximately $131,000. Corebridge Financial Inc. bought a new stake in shares of Metsera in the 1st quarter worth approximately $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Metsera in the 1st quarter worth approximately $248,000. MetLife Investment Management LLC bought a new stake in shares of Metsera in the 1st quarter worth approximately $254,000. Finally, Invesco Ltd. bought a new stake in shares of Metsera in the 1st quarter worth approximately $271,000.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
